AXCELIS TECHNOLOGIES INC (ACLS): what the price requires

At today's price, AXCELIS TECHNOLOGIES INC (ACLS) is priced for today's economics sustained for ~20.0 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ACLS

Headline

FieldValue
TickerACLS
CompanyAXCELIS TECHNOLOGIES INC
Current price$136.75/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed17.4%
Operating margin today11.4%
Margin expansion implied+6.0pp
Must persist for20.0y
Multiple paid45x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 13.9% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~3 years.

Reconcile: at the x-ray's 9.3% required return this reads ~9.1 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history-0.05σ
sustained it ~10 years at this level14%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset3.80x4expensive
Earnings4.19x4expensive
Relative2.00x3expensive
Growth2.30x3expensive

Families that call it expensive: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.

Per-Model Detail (n=14)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$23.875.73xyesFCF base $0.1B, growth -10% (input: historical growth), terminal g 0.5%, WACC 8.9%, 5yr projection
DCF Exit MultipleGrowth$104.491.31xyesExit EV/EBITDA: 34.6x / 36.6x / 38.6x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$76.751.78xyesP/E 25.2x (blended: static sector reference 18x + trailing (TTM) 42x), scenarios: 21.3x / 25.2x / 29.1x (bear / base = reference held flat / bull), EV/EBITDA 19.38x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$35.203.88xyesBV/sh $33.72, ROE (TTM) 9.7%, ke 9.3%
Two-Stage Excess ReturnAsset$35.953.80xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$59.582.30xyesRev $0.8B, growth -11% (input: historical growth; tapered), Terminal P/S: 4.2x / 5.0x / 5.8x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$56.072.44xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.18B × (1−13%) / WACC 8.9% → EPV (no growth)
Residual IncomeAsset$36.083.79xyesBV $33.72 + 5yr PV of (ROE (TTM) 9.7% − Kₑ 9.3%) × BV; BV grows 6.3%/yr
Graham NumberAsset$49.432.77xyes√(22.5 × EPS $3.22 × BVPS $33.72) — Graham's conservative floor
EV/EBITDA RelativeRelative$44.753.06xyesEBITDA $0.12B × sector EV/EBITDA 12.0x
FCF YieldEarnings$30.754.45xyesFCF $88.5M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$23.505.82xyesSBC-adj FCF $0.07B (FCF $0.09B − SBC $0.02B) capitalized at Kₑ
Ben Graham FormulaEarnings$2.7050.65xyesEPS $3.22 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset$2.4855.14xyesBV $33.72 × (ROIC 0.7% / WACC 8.9%) (excluded from median)
P/Sales SectorRelative$68.222.00xyesRevenue $0.85B × sector P/S 2.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$34.813.93xyesEPS $3.22 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$337.7m
Net debt / NOPAT (after-tax)-4.27x (net cash)
Net debt / operating income (pre-tax)-3.71x (net cash)
Interest coverage17.1x
Share count CAGR (buyback)-2.3%
Burning cashno

Bullet Takeaways

Bull Case

Start with how far the price sits above the methods, because it frames what kind of bet a buyer is making. Every valuation family lands below today's price, the asset, earnings-power, peer-multiple, and even forward-growth lenses all read Axcelis as expensive on its current numbers. A price that no standard method reaches is, by definition, paying for something the trailing financials cannot show, and for a cyclical equipment maker that something is the next up-cycle. The bull case is that the market is correctly looking through a trough, valuing the franchise on what it earns at the top of the cycle rather than the bottom.

The substance of the franchise is technology leadership in a narrow, essential niche. Ion implantation is a non-negotiable step in chip fabrication, and Axcelis describes a portfolio built by "scientists and engineers who are adding to our portfolio of patents and proprietary technology to ensure that our investment in technology leadership translates into" products customers depend on. The company is levered to the demand drivers it names in its filing, "the introduction of 5G mobile networks), artificial intelligence, large language models", data analytics, and the Internet of Things, all of which require more silicon and more of the power and memory chips Axcelis equips. Power devices for electrification and the memory rebuild are exactly the markets where its implanters are strongest.

The third leg is a balance sheet built for the downturn. Axcelis holds about $338 million of net cash against roughly $42 million of gross debt, interest is covered more than eighteen times over, and the share count has fallen about 2.3% a year on buybacks. A cyclical company with net cash and no leverage does not have to raise capital at the bottom or cut investment when orders soften; it can keep funding the technology roadmap and retiring stock while weaker competitors retrench. That is the quiet advantage that compounds across cycles: the company that enters the recovery with a full product pipeline and fewer shares outstanding captures more of the upswing. The bull case is that Axcelis is that company, and the price is paying ahead for the recovery it expects.

Bear Case

The bear case for Axcelis is that the customers it most depends on are the ones with the strongest reason to leave. Asia accounts for the overwhelming majority of system sales, ion implanter shipments to Asian customers were 76.0% of total system revenue in 2025, and a large part of that is China. The company's own filing names the danger: increased "U.S. export controls and other political and trade tensions exacerbate the risk that Chinese customers will change suppliers to non-U.S. vendors." China has both the motive and a growing domestic equipment industry, so the threat is not a one-time tariff but a structural substitution: every implanter a Chinese fab buys from a local vendor is one Axcelis never sells again. For a business this concentrated, losing the China channel is not a haircut, it is a reset of the addressable market.

The second problem is the cycle itself, and where the price sits in it. Equipment demand is famously lumpy: capacity gets ordered in waves, and trailing revenue has been declining, with the operating margin near 11.6% rather than the higher levels these companies earn at the peak. The danger in a cyclical is paying a high multiple on trough earnings under the assumption the recovery is both certain and imminent. If the up-cycle is shallower or later than the price assumes, the company is left earning depressed margins against an equity valued for the boom, and cyclicals correct hard when the expected recovery slips.

The valuation makes the asymmetry explicit. At the current price the market is paying about 62 times company-wide operating income, a multiple so high it implies operating profit compounding at its self-funding ceiling for roughly 25 years, and the historical record shows only about 14% of comparable fast-growers sustained that kind of pace even for a decade. No valuation family reaches the price. The balance sheet is pristine and removes any survival risk, but a strong balance sheet does not justify a peak multiple on trough earnings; it only guarantees the company is around to find out whether the recovery arrives. The bear does not need Axcelis to fail. It only needs the recovery to be ordinary rather than extraordinary, and the gap between the price and every method closes downward.

Valuation

The single most useful number here is the multiple the price implies, and it is extreme. At $187.74 the market is paying about 62 times company-wide operating income. Inverted, that asks operating profit to compound at roughly its self-funding ceiling for about 25 years, a pace only about 14% of comparable fast-growers sustained for even a decade. The reason the multiple looks so stretched is that it is measured against trough earnings: this is a cyclical equipment maker in the soft part of its cycle, with an operating margin near 11.6% rather than the level it earns at the top, so the trailing operating income in the denominator is depressed and the multiple it produces is inflated.

That cyclical distortion is why every valuation family sits below the price. The asset-value methods anchor on a book value near $33.72 a share. The earnings-power method, capitalizing normalized operating income with no growth, lands well under the price. The peer-multiple lens, applying the industrial-machinery cohort's multiples, does not reach it either, and even the forward-growth methods fall short. When no family reaches the price, the price is a bet beyond what any standard frame supports, and the honest reading is that the market is valuing Axcelis on a future up-cycle the static methods cannot see rather than on anything it currently earns. The right way to weigh a name like this is on mid-cycle or peak earnings power, not the trailing trough, but even on a generous normalized basis the price leaves little room.

Solvency is the one unambiguous strength and bounds the downside cleanly. Axcelis holds about $338 million of net cash, gross debt of only about $42 million, interest covered more than eighteen times, and a share count that keeps falling. The company will not be forced to raise capital or cut its technology investment at the bottom of the cycle, which is exactly when balance-sheet strength matters most for an equipment maker. So the downside is bounded by a fortress balance sheet and the upside is gated by the timing and depth of the next semiconductor up-cycle, with the price already paid forward for a strong one.

Catalysts

The near-term prints show a business off its lows but not yet in recovery. Axcelis reported first-quarter 2026 revenue of $199.0 million with GAAP diluted EPS of $0.30, after a stronger fourth quarter of 2025 at $238 million of revenue and $1.10 of GAAP EPS. The swing between those quarters is the cyclicality in miniature: order timing, not a structural change in the business, drives much of the quarter-to-quarter move, so the trajectory of bookings matters more than any single print.

The demand catalyst management points to is the memory market and the broader electrification of the economy, both of which lift implant intensity over time. Those are real multi-year drivers, but they are also the ones already embedded in a price that pays a peak multiple, so the catalyst that re-rates the stock would be evidence the up-cycle is arriving sooner and stronger than feared, and the catalyst that breaks it would be further softness in Asian system orders or a tightening of export controls.

Worth flagging plainly: the analysts who cover Axcelis value it well below where it trades, with consensus targets clustered roughly in the $100 to $115 range against a market price near $188. Sentiment is split, with recent Buy and Hold ratings issued within days of each other. That gap between the street's estimate of value and the market price is itself the situation: the price reflects an up-cycle conviction the analysts' models, anchored closer to current earnings, do not share.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 2026 and Q4 2025 results · company commentary, 2026 · analyst consensus, June 2026

View the full interactive ACLS report on boothcheck